- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015; 385:977-1010
- Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International journal of molecular sciences. 2019; 20
- Nero C, Vizzielli G, Lorusso D, Cesari E, Daniele G, Loverro M et al. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine. Journal of experimental & clinical cancer research : CR. 2021; 40:116
- Costa RM, Soto X, Chen Y, Zorn AM, Amaya E spib is required for primitive myeloid development in Xenopus. Blood. 2008; 112:2287-2296
- Ding M, Li Q, Tan X, Zhang L, Tan J, Zheng L Comprehensive pan-cancer analysis reveals the prognostic value and immunological role of SPIB. Aging. 2022; 14:6338-6357
- Ho YJ, Lin YM, Huang YC, Yeh KT, Lin LI, Lu JW Tissue microarray-based study of hepatocellular carcinoma validating SPIB as potential clinical prognostic marker. Acta histochemica. 2016; 118:38-45
- Wang J, Wang X, Guo Y, Ye L, Li D, Hu A et al. Therapeutic targeting of SPIB/SPI1-facilitated interplay of cancer cells and neutrophils inhibits aerobic glycolysis and cancer progression. Clinical and translational medicine. 2021; 11:e588
- Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S et al. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer science. 2016; 107:1270-1280
- Zhao X, Li L, Yuan S, Zhang Q, Jiang X, Luo T SPIB acts as a tumor suppressor by activating the NFkB and JNK signaling pathways through MAP4K1 in colorectal cancer cells. Cell Signal. 2021; 88:110148
- Montes-Moreno S, Ramos-Medina R, Martínez-López A, Barrionuevo Cornejo C, Parra Cubillos A, Quintana-Truyenque S et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood. 2013; 121:643-647
- Uppal S, Medlin E, Felder M, Kapur A, Sterner RC, Vazquez J et al. Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proof-of-concept study. American journal of reproductive immunology (New York, NY : 1989). 2021; 86:e13469
- Wang X, Teng F, Kong L, Yu J PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016; 9:5023-5039
- Shi X, Yun L, Chaoqun Liu L, Ding H, Liang D, Geng F et al. PD-L1 and the Clinical Outcomes of Ovarian Cancer: Meta-Analysis and Bioinformatical Analysis. Asian Pac J Cancer Prev. 2022; 23:2285-2290
- Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016; 352:227-231
- Wu B, Song M, Dong Q, Xiang G, Li J, Ma X et al. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics. 2022; 12:5086-5102
- Hays E, Bonavida B YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updat. 2019; 43:10-28
- Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:20852-20857
- Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M et al. CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. Frontiers in oncology. 2021; 11
- Nabeshima K, Inoue T, Shimao Y, Sameshima T Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002; 52:255-264
- James NE, Miller K, LaFranzo N, Lips E, Woodman M, Ou J et al. Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer. Frontiers in oncology. 2021; 11
- Huang Q, Liu J, Wu S, Zhang X, Xiao Z, Liu Z et al. Spi-B Promotes the Recruitment of Tumor-Associated Macrophages via Enhancing CCL4 Expression in Lung Cancer. Frontiers in oncology. 2021; 11:659131
- Jin J, Du X, Zhou L, Yao D, Zou Q SPI1-related protein inhibits cervical cancer cell progression and prevents macrophage cell migration. The journal of obstetrics and gynaecology research. 2022; 48:2419-2430
- Cojocaru E, Parkinson CA, Brenton JD Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clinical oncology (Royal College of Radiologists (Great Britain)). 2018; 30:515-524
- Peng H, He X, Wang Q Immune checkpoint blockades in gynecological cancers: A review of clinical trials. Acta obstetricia et gynecologica Scandinavica. 2022; 101:941-951
- Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. Journal of cellular physiology. 2019; 234:1313-1325
- Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104:3360-3365
- Baş Y, Koç N, Helvacı K, Koçak C, Akdeniz R, Şahin HHK Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer. Translational oncology. 2021; 14:100994
- Dumitru A, Dobrica EC, Croitoru A, Cretoiu SM, Gaspar BS Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. International journal of molecular sciences. 2022; 23
- Cho MS, Lee H, Gonzalez-Delgado R, Li D, Sasano T, Carlos-Alcalde W et al. Platelets Increase the Expression of PD-L1 in Ovarian Cancer. Cancers. 2022; 14
- Lin J, Guo D, Liu H, Zhou W, Wang C, Müller I et al. The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. Cancer immunology research. 2021; 9:1413-1424
- Zuo Y, Zheng W, Liu J, Tang Q, Wang SS, Yang XS MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 2020; 67:93-101
- Wu F, Tian F, Qin C, Qin X, Zeng W, Liu X et al. Peroxiredoxin2 regulates trophoblast proliferation and migration through SPIB-HDAC2 pathway. Experimental cell research. 2023; 422:113428
- Zhang H, Wang G, Zhou R, Li X, Sun Y, Li Y et al. SPIB promotes anoikis resistance via elevated autolysosomal process in lung cancer cells. The FEBS journal. 2020; 287:4696-4709
- Carey P, Low E, Harper E, Stack MS Metalloproteinases in Ovarian Cancer. International journal of molecular sciences. 2021; 22
- Hira-Miyazawa M, Nakamura H, Hirai M, Kobayashi Y, Kitahara H, Bou-Gharios G et al. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. International journal of oncology. 2018; 52:379-388
- Chen YL, Wang GX, Lin BA, Huang JS MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer. Cell Biol Int. 2020; 44:1224-1236
- Roshani Asl E, Rasmi Y, Baradaran B MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling. Journal of cellular physiology. 2021; 236:7071-7087
- Krafft U, Olah C, Reis H, Kesch C, Darr C, Grünwald V et al. High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. Cancers. 2021; 13
- Ye Y, Kuang X, Xie Z, Liang L, Zhang Z, Zhang Y et al. Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1. Genome medicine. 2020; 12:83
- Mimura K, Teh JL, Okayama H, Shiraishi K, Kua LF, Koh V et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer science. 2018; 109:43-53
- Padmanabhan S, Gaire B, Zou Y, Uddin MM, Vancurova I IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Cell Signal. 2022; 97:9
- Chen B, Hu J, Hu X, Chen H, Bao R, Zhou Y et al. DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion. Nat Commun. 2022; 13:022-29754
- Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021; 12:021-04047
- Liu F, Liu J, Zhang J, Shi J, Gui L, Xu G Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer. Cancer Biol Ther. 2020; 21:963-971
- Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S et al. Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1. Mol Cancer Ther. 2018; 17:1941-1950
|
